Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Sana Biotechnology Inc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.13, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | SANA | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $15.75 | $5.92 |
52-Week Low | $9.98 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $11.24, down 3.27% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock faces critical support at $11 and resistance at $12. Recent news highlights consistent weekly dividend distributions from YieldMax ETFs, though analyst reports express concerns about NAV erosion despite the high yield strategy.
The outlook for AMZY is mixed; the bullish technical trend and high dividend yield present income opportunities, but fundamental risks include potential NAV erosion and underperformance relative to Amazon. Investors should weigh the attractive weekly distributions against the sustainability of the option income strategy and amplified downside risks highlighted by analysts.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
